 |
|
Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
Seong Woo Go, Boo Kyeong Kim, Sung Hak Lee, Tae-Jung Kim, Joo Yeon Huh, Jong Min Lee, Jick Hwan Hah, Dong Whi Kim, Min Jung Cho, Tae Wan Kim, Ji Young Kang
Tuberc Respir Dis. 2013;75(6):256-259. Published online 2013 Dec 24 DOI: https://doi.org/10.4046/trd.2013.75.6.256
|
|
Citations to this article as recorded by
 Imatinib-induced irreversible interstitial lung disease
Ping Zhang, Jingfeng Huang, Fangfang Jin, Jiaohai Pan, Guifang Ouyang
Medicine.2019; 98(8): e14402. CrossRef Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword
Ahmet Emre Eskazan
Acta Oncologica.2019; 58(1): 123. CrossRef Pneumonitis After Precision Oncology Therapies: A Concise Review
Akash Jain, Vickie R. Shannon, Ajay Sheshadri
Journal of Immunotherapy and Precision Oncology.2018; 1(1): 26. CrossRef European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann, R E Clark
Leukemia.2016; 30(8): 1648. CrossRef Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R. Shah
Drug Safety.2016; 39(11): 1073. CrossRef Imatinib
Reactions Weekly.2014; 1521(1): 85. CrossRef
|